AnxA2 peptides presented by MHC class II-positive cancer cells can also activate antigen-specific T cells and thus produce an immune response that is potentially useful in immunotherapy (Heinzel et al., 2001; Zheng and Jaffee, 2012; Weyd, 2016). The gene discussed is ANXA2; the disease is cancer.